A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation

[1]  M. Maris,et al.  Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. , 2003, Blood.

[2]  L. Isola,et al.  Low-dose total body irradiation, fludarabine, and antithymocyte globulin conditioning for nonmyeloablative allogeneic transplantation. , 2003, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[3]  N. Schmitz,et al.  An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation , 2003, Bone Marrow Transplantation.

[4]  M. Maris,et al.  Allografting after nonmyeloablative conditioning as a treatment after a failed conventional hematopoietic cell transplant. , 2003, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[5]  R. Storb,et al.  Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissio , 2003, Blood.

[6]  L. Rybicki,et al.  A multivariable analysis of factors influencing mucositis after autologous progenitor cell transplantation , 2002, Bone Marrow Transplantation.

[7]  Shaji K. Kumar,et al.  Omission of day +11 methotrexate after allogeneic bone marrow transplantation is associated with increased risk of severe acute graft-versus-host disease , 2002, Bone Marrow Transplantation.

[8]  R. Storb,et al.  Decreased transfusion requirements for patients receiving nonmyeloablative compared with conventional peripheral blood stem cell transplants from HLA-identical siblings. , 2001, Blood.

[9]  F. Spijkervet,et al.  Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  N. Chao,et al.  Acute graft-vs-host disease: pathobiology and management. , 2001, Experimental hematology.

[11]  F. Locatelli,et al.  Cyclosporin A and short-term methotrexate versus cyclosporin A as graft versus host disease prophylaxis in patients with severe aplastic anemia given allogeneic bone marrow transplantation from an HLA-identical sibling: results of a GITMO/EBMT randomized trial. , 2000, Blood.

[12]  E. Lanino,et al.  Mycophenolate mofetil (MMF) as therapy for refractory chronic GVHD (cGVHD) in children receiving bone marrow transplantation , 2000, Bone Marrow Transplantation.

[13]  J. Epstein,et al.  Routine dental diagnostic imaging in hematopoietic cell transplantation. , 1999, Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics.

[14]  J. Epstein,et al.  Oral mucositis in myelosuppressive cancer therapy. , 1999, Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics.

[15]  G. Vogelsang,et al.  Salvage therapy for refractory chronic graft-versus-host disease with mycophenolate mofetil and tacrolimus , 1999, Bone Marrow Transplantation.

[16]  R. Naumann,et al.  Mycophenolate mofetil and cyclosporine as graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation. , 1999, Transplantation.

[17]  A. Fauser,et al.  Efficacy and safety of mycophenolate mofetil for the treatment of acute and chronic GVHD in bone marrow transplant recipient. , 1998, Transplantation proceedings.

[18]  D. Renlund,et al.  A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate Mofetil Investigators. , 1998, Transplantation.

[19]  S. Sonis,et al.  The impact of mucositis on α‐hemolytic streptococcal infection in patients undergoing autologous bone marrow transplantation for hematologic malignancies , 1998, Cancer.

[20]  H. Deeg,et al.  Synergism between mycophenolate mofetil and cyclosporine in preventing graft-versus-host disease among lethally irradiated dogs given DLA-nonidentical unrelated marrow grafts. , 1998, Blood.

[21]  A. Gratwohl,et al.  A survey of the prophylaxis and treatment of acute GVHD in Europe: a report of the European Group for Blood and Marrow Transplantation (EBMT) , 1997, Bone Marrow Transplantation.

[22]  J. Wingard,et al.  The outcome of unrelated donor bone marrow transplantation in patients with hematologic malignancies using tacrolimus (FK506) and low dose methotrexate for graft-versus-host disease prophylaxis. , 1997, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[23]  A. Deisseroth,et al.  Tacrolimus and Minidose Methotrexate for Prevention of Acute Graft- Versus-Host Disease After Matched Unrelated Donor Marrow Transplantation , 1996 .

[24]  K. Atkinson,et al.  Omission of day 11 methotrexate does not appear to influence the incidence of moderate to severe acute graft-versus-host disease, chronic graft-versus-host disease, relapse rate or survival after HLA-identical sibling bone marrow transplantation. , 1995, Bone marrow transplantation.

[25]  Sollinger Hw.  Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. , 1995 .

[26]  H. Deeg,et al.  Methotrexate, cyclosporine, or both to prevent graft-versus-host disease after HLA-identical sibling bone marrow transplants for early leukemia? , 1993, Blood.

[27]  M. Dimopoulos,et al.  An effective acute graft‐vs.‐host disease prophylaxis with minidose methotrexate, cyclosporine, and single‐dose methylprednisolone , 1991, American journal of hematology.

[28]  A. Rimm,et al.  T-cell depletion of HLA-identical transplants in leukemia. , 1991, Blood.

[29]  H. Deeg,et al.  Graft‐versus‐host disease prevention by methotrexate combined with cyclosporin compared to methotrexate alone in patients given marrow grafts for severe aplastic anaemia: long‐term follow‐up of a controlled trial , 1989, British journal of haematology.

[30]  H. Deeg,et al.  Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: long-term follow-up of a controlled trial. , 1989, Blood.

[31]  H. Deeg,et al.  Hyperacute graft-v-host disease in patients not given immunosuppression after allogeneic marrow transplantation. , 1986, Blood.

[32]  H. Deeg,et al.  Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. , 1986, The New England journal of medicine.

[33]  H. Sollinger.  Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. , 1995, Transplantation.

[34]  K. Akashi,et al.  Cyclosporine combined with methylprednisolone or methotrexate in prophylaxis of moderate to severe acute graft-versus-host disease. , 1993, Bone marrow transplantation.

[35]  C. Zywietz,et al.  Stabilität der Vermessung kleiner Biosignale In Abhängigkeit von Abtastrate und Störpegel , 1985 .